4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

SCHEDULE 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

SCHEDULE 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

DEF 14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

PRE 14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

EFFECT - Transcode Therapeutics, Inc. (0001829635) (Filer)

D - Transcode Therapeutics, Inc. (0001829635) (Filer)

S-1 - Transcode Therapeutics, Inc. (0001829635) (Filer)

No significant safety or dose limiting toxicities reportedPK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial resultsBOSTON, Feb. 6, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate.  The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its review of Cohort 1 and 2 safety and pharmacokinetic (PK) data and is monitoring Cohort 3 as preliminary data becomes av

BOSTON, Feb. 4, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on February 4, 2025 (the "Special Meeting") has been adjourned until February 25, 2025 at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on December 30, 2024 (the "Special Meeting Pro

Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2 No significant safety or dose limiting toxicities reported in Cohorts 1 and 2PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial resultsBOSTON, Jan. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with TTX-MC138, its lead candidate.  The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its favorable

TransCode shares to remain listed on Nasdaq BOSTON, Jan. 7, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Company has regained compliance with Listing Rules 5550(a)(2) and 5550(b)(1), the Exchange's minimum bid price and shareholders' equity rules, respectively. The Company has also resolved the violation regarding Listing Rule 5635 (the "Shareholder Approval Rule") by obtaining shareholder ratification of a July 2024 equity transaction. As a result, the Company's shares will remain lis

Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 No significant safety or dose limiting toxicities reported in Cohort 2New patients currently being evaluated for eligibility in Cohort 3PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial resultsBOSTON, Dec. 18, 2024 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on its favorabl

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time December 4, 2024, for its 1-for-33 reverse stock split. TransCode's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on December 4, 2024, under the current trading symbol, "RNAZ." The reverse stock split was approved by TransCode's stockholders and Board of Directors on November 22, 2024, and is intended to increase the per

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8 million before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for general corporate purposes and working capital. In connection with the private placement, the Company is planning to issue an aggregate of 21,220,160 sh

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode's stockholders on November 22, 2024, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode's

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ:RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholders, At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below. Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadl

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode's request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D). The listing standards of issue included the bid price requirement in Nasdaq Listing Rule 5550(a)(2)

SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13D - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)